The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy.
Inclusion Criteria
1.
Age ≥ 18 years
2.
Confirmation of resectable disease by real-time central imaging review by the Alliance Imaging Core Lab at IROC Ohio.
3.
Determined to be appropriate candidate for curative-intent pancreatectomy
Exclusion Criteria
1.
Prior radiation therapy, chemotherapy, targeted therapy, investigational therapy, or surgery for pancreatic cancer.
2.
Pregnant or nursing
3.
Comorbid conditions that would prohibit curative-intent pancreatectomy
Study Requirements
This study has 2 study groups. You will be told which group you are in.
- Group 1: Sujects will get the usual four-drug regimen used to treat this type of cancer, FOLFIRINOX on the first and second day of each 14-day cycle. Sujects will get this drug regimen for 8 cycles, then have the usual surgery to remove the pancreatic cancer, and then get the usual drug regimen for 4 more cycles.
- Group 2: Subjects will get the usual four-drug regimen used to treat this type of cancer, FOLFIRINOX on the first and second day of each 14-day cycle. Subjects will then have the usual surgery to remove the pancreatic cancer, then get the usual drug regimen for 12 cycles.
